TIAP funds and develops early-stage innovations in therapeutics, medical devices, and digital health into successful Canadian companies. Working with top universities and hospitals, TIAP advances promising technologies with the potential to impact patients. Supported by industry advisors and matched funding from investors, TIAP has been a leader in commercializing research since 2008, with backing from government and strategic partners like Amgen and Evotec SE.